The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ability to treat corneal persistent epithelial defects (PEDs) or corneal ...

One eye with membranous keratoconjunctivitis with symblepharon showed resolution of corneal epithelial defect on the seventh day. The ocular surface healed completely with no symblepharon at the ...

Patients with limbal deficiency may benefit from limbal stem cell transplantation to alleviate persistent epithelial defects, maintain conjunctivalization regression and corneal avascularity ...

Investigators recommend a dose of 0.2 mg/mL losartan 6 times per day for patients with a current corneal epithelial defect. Topical losartan for the treatment of scarring corneal fibrosis mediated by ...

At stage 2, patients present with persistent epithelial defects and might complain of foreign body sensation and discomfort but often no pain because corneal sensation is impaired, he said.

With its acceptance by the NMPA, NVK002 is now under regulatory review across three major global markets: the United States, ...

presbyopia and cornea epithelial defects. Many of the drugs are being produced in its state-of-the-art and fully functional development and production facility in Nansha, Guangzhou, Guangdong ...

Lufepirsen is under clinical development by Amber Ophthalmics and currently in Phase II for Persistent Corneal Epithelial Defects. According to GlobalData, Phase II drugs for Persistent Corneal ...

Kala Pharmaceuticals Inc (NASDAQ:KALA)., a micro-cap biotech company valued at $40.13 million, has seen its stock reach a 52-week high, hitting an impressive $8.81. This peak reflects a significant ...

In vitro assays using human corneal epithelial cells-transformed (HCE-T ... as a novel strategy to accelerate healing of corneal defects while mitigating vision impairment (Scheme 1). Hemoglobin ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...